Intellikine's Series A Round

Intellikine raised a round of funding on June 18, 2007.

Intellikine is developing small molecule therapies targeting the PI3K/mTOR pathway for treatment of cancer, inflammation and autoimmune diseases. In December 2011, Intellikine was acquired by Taked…

Articles about Intellikine's Series A Round: